The Food & Drug Administration’s brand name review process appears to have settled into a more comfortable and predictable part of the new drug review process thanks to recently issued and updated guidance documents for industry on best practices.
The Center for Drug Evaluation & Research approved 86% of proprietary trade names submitted by sponsors of new drugs and biologics in the first half of fiscal year 2015 –...